Kane Biotech highlights data on revyve biofilm action

Executive Summary

• Kane Biotech announced the publication of a peer-reviewed article in Frontiers in Antibiotics detailing the efficacy of its revyve antimicrobial wound gel against antibiotic-tolerant biofilms.
• The study demonstrates that revyve effectively eliminates mature Staphylococcus aureus and Pseudomonas aeruginosa biofilms, even after antibiotic pretreatment, driving bacterial counts below detectable limits within 24 to 72 hours.
• The publication reinforces the commercial and scientific value of revyve, which is already FDA 510(k) cleared and Health Canada-approved, supporting the company's mission to address biofilm-related challenges in wound care.

Key Details

• Publication Details: The article, titled "Efficacy of a Novel Thermo-Reversible Wound Gel Against Antibiotic Tolerant Biofilm," was published in Frontiers in Antibiotics, a peer-reviewed, open-access journal.
• Authors: First-authored by Dr. Jeyachchandran Visvalingam (Internal R&D Leader at Kane Biotech) and including contributions from Dr. Sarvesh Logsetty (Burn and Trauma Surgeon at the Max Rady College of Medicine, University of Manitoba).
• In Vitro/Ex Vivo Results: revyve demonstrated strong activity against antibiotic-tolerant biofilms in both in vitro and ex vivo models.
• Specific Efficacy: Following antibiotic pretreatment that generated highly antibiotic-tolerant cells, revyve achieved large log-scale reductions in surviving populations.
• Timeline of Action: The gel often drove bacterial counts below detectable limits within 24 to 72 hours.
• Target Pathogens: The study specifically targeted Staphylococcus aureus and Pseudomonas aeruginosa.
• Regulatory Status: revyve antimicrobial wound gel is U.S. FDA 510(k) cleared and Health Canada-approved. revyve antimicrobial wound gel spray and revyve antimicrobial skin and wound cleanser are also FDA 510(k) cleared.

Notable Quotes

• "Having our research published in Frontiers in Antibiotics as an open-access article is an important milestone for Kane Biotech as we continue to commercialize revyve across wound and burn care markets... This publication reinforces the strength of our technology and supports our mission to bring advanced, biofilm-targeted solutions to patients." — Dr. Robert Huizinga, Interim Chief Executive Officer of Kane Biotech.